Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Total Liabilities : $82,483.00 Mil (As of Mar. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Bristol-Myers Squibb Co Total Liabilities?

Bristol-Myers Squibb Co's Total Liabilities for the quarter that ended in Mar. 2024 was $82,483.00 Mil.

Bristol-Myers Squibb Co's quarterly Total Liabilities increased from Sep. 2023 ($62,201.00 Mil) to Dec. 2023 ($65,674.00 Mil) and increased from Dec. 2023 ($65,674.00 Mil) to Mar. 2024 ($82,483.00 Mil).

Bristol-Myers Squibb Co's annual Total Liabilities declined from Dec. 2021 ($73,308.00 Mil) to Dec. 2022 ($65,702.00 Mil) and declined from Dec. 2022 ($65,702.00 Mil) to Dec. 2023 ($65,674.00 Mil).

Bristol-Myers Squibb Co Total Liabilities Historical Data

The historical data trend for Bristol-Myers Squibb Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Total Liabilities Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

78,246.00

80,599.00

73,308.00

65,702.00

65,674.00

Bristol-Myers Squibb Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															62,395.00	61,459.00	62,201.00	65,674.00	82,483.00

Bristol-Myers Squibb Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bristol-Myers Squibb Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	22262	+	(38183	+	3684
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1065	+	480)
	=	65,674.00

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	95159	-	29485
	=	65,674.00

Bristol-Myers Squibb Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	25822	+	(51050	+	3942
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1192	+	477)
	=	82,483.00

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	99031	-	16548
	=	82,483.00

Bristol-Myers Squibb Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY.R) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.